Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis

Saved in:
Bibliographic Details
Published inAmerican journal of hematology Vol. 93; no. 7; pp. E159 - E161
Main Authors Caocci, Giovanni, Mulas, Olga, Annunziata, Mario, Luciano, Luigiana, Bonifacio, Massimiliano, Orlandi, Ester Maria, Pregno, Patrizia, Galimberti, Sara, Russo Rossi, Antonella, Abruzzese, Elisabetta, Iurlo, Alessandra, Martino, Bruno, Sgherza, Nicola, Binotto, Gianni, Castagnetti, Fausto, Gozzini, Antonella, Fozza, Claudio, Bocchia, Monica, Sicuranza, Anna, Stagno, Fabio, Efficace, Fabio, Usala, Emilio, De Gregorio, Fiorenza, Scaffidi, Luigi, Elena, Chiara, Pirillo, Francesca, Baratè, Claudia, Trawinska, Malgorzata Monika, Cattaneo, Daniele, Labate, Claudia, Gugliotta, Gabriele, Molica, Matteo, Specchia, Giorgina, La Nasa, Giorgio, Foà, Robin, Breccia, Massimo
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.07.2018
Subjects
Chronic myeloid leukemia
Hematology
Myeloid leukemia
Prophylaxis
Risk factors
Toxicity
Tyrosine kinase inhibitors
Online AccessGet full text
ISSN0361-8609
1096-8652
1096-8652
DOI10.1002/ajh.25102

Cover

More Information
Bibliography:Funding information
None
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Correspondence-1
ISSN:0361-8609
1096-8652
1096-8652
DOI:10.1002/ajh.25102